Gene Mutation Clinical Trial
Official title:
Safety and Tolerability of RAG-17 in the Treatment of Amyotrophic Lateral Sclerosis Patients With SOD1 Gene Mutation
| Verified date | June 2023 |
| Source | Beijing Tiantan Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics of RAG-17 in adult amyotrophic lateral sclerosis (ALS) patients with SOD1 mutation. Patients will receive drug treamtent via dose escalation which ranging from minimum of 60 mg to the maximum tolerated dose (MTD), after reaching the tolerated dose, a fixed dose of the drug is given once every two months for continuous treatment, and the total treatment cycle is 8 months. The duration of this study is two years.
| Status | Enrolling by invitation |
| Enrollment | 6 |
| Est. completion date | February 28, 2024 |
| Est. primary completion date | February 28, 2024 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 75 Years |
| Eligibility | Inclusion Criteria: - Patients who are judged by professional medical staff to still be able to carry out the clinical trial project cycle; - 18 years old = age = 75 years old, males or females; - ALS patients with confirmed SOD1 gene mutations document (known SOD1 mutation sites and related disease progression have been reported); - Forced vital capacity = 80% of predicted vital capacity during the screening period; - Diagnosis of confirmed or probable familial or sporadic ALS in accordance with the revised EI Escorial diagnostic criteria for amyotrophic lateral sclerosis of the World Federation of Neurology; - The patient or patient's legal representative clearly understands and voluntarily participates in the study and signs the informed consent form; - Subjects (including male subjects) are willing to have no birth plan and voluntarily take effective contraceptive measures during the entire study period and within 3 months after the end of the study, and have no plan to donate sperm or eggs. Exclusion Criteria: - Patients with SOD1 mutations occurring at nucleotides 44 to 66 (calculated from the start of SOD1 protein translation), patients with P.F21C mutation; - Patients who have previously received or are currently receiving Tofersen treatment; - HIV test positive or history of positive tests; - Positive hepatitis C virus antibody or history of positive tests; - Active hepatitis B infection (positive hepatitis B surface antigen and/or positive hepatitis B core antibody); - Have used other investigational drugs within 1 month or within 5 drug half-lives; - Diseases and deformities of the lumbar spine; - Have other conditions known to be associated with motor neuron dysfunction that may confuse or obscure an ALS diagnosis; - Other psychiatric disorders diagnosed according to DSM-V diagnostic criteria, or significant suicide intent; - With severe hepatic insufficiency, renal insufficiency or severe cardiac insufficiency (severe hepatic insufficiency refers to ALT value=2.0 times the upper limit of normal value or AST value=2.0 times the upper limit of normal value; severe renal insufficiency refers to CRE=1.5 times the upper limit of normal value or eGFR<40mL/min/1.73m2; severe cardiac insufficiency refers to NYHA class 3-4); - Permanently dependent on ventilator-assisted ventilation; - History of alcohol and drug abuse; - Patients who are pregnant, breast-feeding, or who are likely to become pregnant and plan to become pregnant; - Patients participating in other clinical trials or using other biological agents, drugs or devices under investigation; - Patients who have received any vaccinations within 28 days; - Contraindications to MRI (eg, claustrophobia); - Unable to be cooperative and complete the follow-up due to other reasons. |
| Country | Name | City | State |
|---|---|---|---|
| China | Beijing Tiantan Hospital | Beijing |
| Lead Sponsor | Collaborator |
|---|---|
| Beijing Tiantan Hospital | Ractigen Therapeutics |
China,
Amyotrophic Lateral Sclerosis (ALS) Fact Sheet. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/amyotrophic-lateral-sclerosis-als-fact-sheet#treatment. October 2022.
Barrington CJ, Burruano M, Carney C, Choi J, Januska J, Lachuk L, Oskarsson B, Rodriguez C, Speicher L, Tereso G. Addressing the role of edaravone in the management of amyotrophic lateral sclerosis and gaps in care and access: expert panel recommendations. Am J Manag Care. 2021 Aug;27(12 Suppl):S231-S237. doi: 10.37765/ajmc.2021.88732. — View Citation
Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017 Jul 13;377(2):162-172. doi: 10.1056/NEJMra1603471. No abstract available. — View Citation
Chattopadhyay M, Valentine JS. Aggregation of copper-zinc superoxide dismutase in familial and sporadic ALS. Antioxid Redox Signal. 2009 Jul;11(7):1603-14. doi: 10.1089/ars.2009.2536. — View Citation
Chen L, Zhang B, Chen R, Tang L, Liu R, Yang Y, Yang Y, Liu X, Ye S, Zhan S, Fan D. Natural history and clinical features of sporadic amyotrophic lateral sclerosis in China. J Neurol Neurosurg Psychiatry. 2015 Oct;86(10):1075-81. doi: 10.1136/jnnp-2015-310471. Epub 2015 Jun 29. — View Citation
Emery AE, Holloway S. Familial motor neuron diseases. Adv Neurol. 1982;36:139-47. No abstract available. — View Citation
Feldman EL, Goutman SA, Petri S, Mazzini L, Savelieff MG, Shaw PJ, Sobue G. Amyotrophic lateral sclerosis. Lancet. 2022 Oct 15;400(10360):1363-1380. doi: 10.1016/S0140-6736(22)01272-7. Epub 2022 Sep 15. — View Citation
Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, Kalra S, Katz JS, Mitsumoto H, Rosenfeld J, Shoesmith C, Strong MJ, Woolley SC; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009 Oct 13;73(15):1218-26. doi: 10.1212/WNL.0b013e3181bc0141. Erratum In: Neurology. 2009 Dec 15;73(24):2134. Neurology. 2010 Mar 2;74(9):781. — View Citation
Rosenbohm A, Liu M, Nagel G, Peter RS, Cui B, Li X, Kassubek J, Rothenbacher D, Lule D, Cui L, Ludolph AC; ALS Registry Swabia Study Group. Phenotypic differences of amyotrophic lateral sclerosis (ALS) in China and Germany. J Neurol. 2018 Apr;265(4):774-782. doi: 10.1007/s00415-018-8735-9. Epub 2018 Feb 1. — View Citation
Shahrizaila N, Sobue G, Kuwabara S, Kim SH, Birks C, Fan DS, Bae JS, Hu CJ, Gourie-Devi M, Noto Y, Shibuya K, Goh KJ, Kaji R, Tsai CP, Cui L, Talman P, Henderson RD, Vucic S, Kiernan MC. Amyotrophic lateral sclerosis and motor neuron syndromes in Asia. J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):821-30. doi: 10.1136/jnnp-2015-312751. Epub 2016 Apr 19. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Lung function (including forced vital capacity) | Changes in lung function (including forced vital capacity) in adult ALS patients treated with RAG-17 on day 15, day 29, day 90, and day 180 | day 15, day 29, day 90, and day 180 | |
| Other | Severity of Fatigue (Fatigue Severity Scale - FSS) | Fatigue Severity Scale(FSS) is a questionnaire-based scale that is used to measure the change in severity of fatigue in adult ALS patients on day 15, day 29, day 90, day 180 after RAG-17 treatment. FSS scale is 9-items questionnaire, and each item is scored on a 7 points scale from 1 (strongly disagree) to 7 (strongly agree). The minimum score in total is 9 points, and the maximum score possible is 63. The higher the score means the greater fatigue severity. | day 15, day 29, day 90, and day 180 | |
| Other | Muscle strength (Medical Research Council Scale - MRC Scale) | Medical Research Council Scale (MRC Scale) is an assessment that is used to measure the change in muscle strength of abductor pollicis brevis muscle, abductor digiti minimi, and tibial anterior muscle in adult ALS patients treated with RAG-17 on day 15, day 29, day 90, day180. MRC Scales ranges from grade 0 to grade 5, where grade 0 means no muscle contraction, grade 5 means muscle has full strength. | day 15, day 29, day 90, and day 180 | |
| Other | Electromyography (EMG) measures | Electromyography(EMG) is used to determine the functional performance of muscle and the index change including compound muscle action potential(CAMP)of EMG in adult ALS patients from baseline on day 29, day 90, and day180 after RAG-17 treatment | day 29, day 90, day 180 | |
| Other | Electromyography (EMG) Measures | Changes in EMG measures (motor unit number index) from baseline on day 29, day 90, day180 after RAG-17 treatment in adult ALS patients | day 29, day 90, day 180 | |
| Other | Electromyography (EMG) Measures | Changes in EMG measures (motor unit size index) from baseline on day 29, day 90, day180 after RAG-17 treatment in adult ALS patients | day 29, day 90, day 180 | |
| Other | 7T magnetic resonance imaging measures | 7T magnetic resonance imaging (7T MRI) is used to measure the change in the value of body indexes in adult ALS patients treated with RAG-17 on day 29, day 90 and day180. | day 29, day 90 and day 180 | |
| Other | Kinetic Gait Analysis-Gait Function | Kinetic gait analysis is used to determine the forces created by and during movement, and measurements are collected to further determine the change in gait functions of of adult ALS patients on day 15, day 29, day 90, and day180 after RAG-17 treatment. | day15, day 29, day 90, and day180 | |
| Other | Kinematic Gait Analysis-Gait Function | Kinematic gait is studied via 3D motion analysis, Construction of the coordinates and orientation of the rigid body segments allow calculation of joint angles of the proximal and distal segment, joint angular velocity, and joint acceleration. Measurements are collected for each joint in all three cardinal planes of motion, and it further measures the change in gait functions of of adult ALS patients on day 15, day 29, day 90, and day180 after RAG-17 treatment. | day15, day 29, day 90, and day180 | |
| Other | Short Physical Performance Battery (SPPB) - Gait Function | Short Physical Performance Battery (SPPB) is an objective assessment that is used to measure the change in gait functions including balance, lower extremity strength, and functional capacity of of adult ALS patients on day 15, day 29, day 90, and day 180 after RAG-17 treatment. The test includes three different assessments: walking, sit-to-stand and balance. A 0- to 12-point scale is used to score the sum of the three assessments with higher point values corresponding with greater levels of physical function and lower disability, and vise versa. | day 15, day 29, day 90, and day 180 | |
| Other | Scale for the Assessment and Rating of Ataxia (SARA) - First Item: Gait | Scale for the Assessment and Rating of Ataxia (SARA) is a performance based scale that has eight categories to assess different impairments. The first category - gait of SARA is used to measure the change in gait function of adult ALS patients on day 15, day 29, day 90, and day 180 after RAG-17 treatment. Gait function is scored from 0point (normal) to 8points (unable to walk). | day 15, day 29, day 90, and day 180 | |
| Other | 6-meter Walking Speed - Gait function | 6-meter walking speed is a performance test to assess walking speed over a short distance, which determine the changes in gait function of adult ALS patients on day 15, day 29, day 90, and day 180 after RAG-17 treatment. The test will be perform in 4 trials, as the first trial is practise trial, and the average of last three trials are calculated. | day 15, day 29, day 90, and day 180 | |
| Other | The Modified Norris Test Score - Functional ability | The Modified Norris Test Score is a rating scale that is used to measure the change in functional ability of adult ALS patients on day 15, day 29, day 90, and day 180 after RAG-17 treatment. This scale is composed with two parts: the Limb Norris Scale (21 items) and the Norris Bulbar Scale (13 items), each item is scored from 0 point (cannot do anything) to 3 points (normal). | day 15, day 29, day 90, and day 180 | |
| Other | Amyotrophic Lateral Sclerosis Assessment Questionnaire -40 (ALSAQ-40) - The Quality of Life | Amyotrophic Lateral Sclerosis Assessment Questionnaire -40 (ALSAQ-40) is a patient self-report health status PRO that is used to measure the changes in the quality of life of adult ALS patients treated with RAG-17 on day 15, day 29, day 90, and day180. There are 40 items in ALSAQ-40 with 5 domains: physical mobility (10 items), activities of daily living and independence (10 items), eating and drinking (3 items), communication (7 items), emotional reactions (10 items), each domain has a total score of 100 points, where 0 point means the worst health condition, and 100points means the best health condition. | day 15, day 29, day 90, and day 180 | |
| Other | The EuroQol 5 Dimension 5 Level (EQ-5D-5L)- The Quality of Life | The EuroQol 5 Dimension 5 Level (EQ-5D-5L) is a self-report survey that is used to measure the changes in the quality of life of adult ALS patients treated with RAG-17 on day 15, day 29, day 90, and day180. EQ-5D-5L contains 5 domains including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, and each domain is scored on a 5-level severity from Level1(no difficulty) to Level5 (extreme difficulty). | day 15, day 29, day 90, and day 180 | |
| Other | Hamilton Anxiety Scale (HAM-A) - The Quality of Life | Hamilton Anxiety Scale (HAM-A) is a rating scale that is used to measure the changes in severity of anxiety of adult ALS patients treated with RAG-17 on day 15, day 29, day 90, and day180. The scale is composed of 14 items, Each item is scored on a scale of 0 (no symptom) to 4 (severe), with a total score range of 0 to 56, where <7 means no symptom of anxiety, over 24 means mild to moderate severity, >29 means extreme severity. | day 15, day 29, day 90, and day 180 | |
| Other | Hamilton Depression Scale (HAM-D)-The Quality of Life | Hamilton Depression Scale (HAM-D) is a rating scale that is used to measure the changes in severity of depression of adult ALS patients treated with RAG-17 on day 15, day 29, day 90, and day180. For the 17-item version, scores can range from 0 to 54. Scores between 0 and 6 indicate a normal person , scores between 7 and 17 indicate mild depression, scores between 18 and 24 indicate moderate depression, and scores over 24 indicate severe depression. | day 15, day 29, day 90, and day 180 | |
| Other | King's Staging System - Clinical staging of patients | King's staging system is used to measure the change in clinical stages of adult ALS patients on day 15, day 29, day 90, and day 180 after RAG-17 treatment. The King's staging system consists of five disease stages, with Stage 5 being death. Stage 4 is nutritional failure.Stages 1-3 are based upon the number of El Escorial central nervous system (CNS) regions involved in the disease, measured by weakness, wasting, spasticity, dysphagia, or dysarthria. | day 15, day 29, day 90, and day 180 | |
| Other | The Milano-Torino (MiToS) Staging - Clinical staging of patients | The Milano-Torino (MiToS) Staging is used to measure the change in clinical stages of adult ALS patients on day 15, day 29, day 90, and day 180 after RAG-17 treatment. The Milano-Torino (MiToS) Staging is composed with six stages, where stage 0 is no functional impairment, stage 1 is loss of one type of function, stage 2 is loss of two type of function, stage 3 is loss of three type of function, stage 4 is loss of four type of function, and stage 5 is death. | day 15, day 29, day 90, and day 180 | |
| Primary | Adverse events (AE) and serious adverse events (SAE) | The incidence of adverse events (AE) and serious adverse events (SAE) within 180 days after RAG-17 treatment, and number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) V5.0 | Within 180 days after treatment | |
| Primary | Clinical laboratory examination index | Monitor the abnormal change of clinical laboratory Index generated from general examination results before RAG-17 treatment, and within 180days after RAG-17 treatment, which including blood testing and urine testing. Eventually to determine the safety and tolerability of RAG-17 on adult ALS patients. | Before RAG-17 treatment and within 180 days after treatment | |
| Primary | Physiological Parameter-Vital Sign: Body Temperature | Change in vital signs are monitored within 180 days after RAG-17 treatment to determine the safety and tolerability of RAG-17 on adult ALS patients. Vital sign that is measured including body temperature in degree Celsius. | Within 180 days after treatment | |
| Primary | Physiological Parameter-Vital Sign: Pulse Rate | Change in vital signs are monitored within 180 days after RAG-17 treatment to determine the safety and tolerability of RAG-17 on adult ALS patients. Vital sign that is measured including pulse rate in beats per minute. | Within 180 days after treatment | |
| Primary | Physiological Parameter-Vital Sign: Respiration Rate | Change in vital signs are monitored within 180 days after RAG-17 treatment to determine the safety and tolerability of RAG-17 on adult ALS patients. Vital sign that is measured including respiration rate in breaths per minute. | Within 180 days after treatment | |
| Primary | Physiological Parameter-Vital Sign: Blood Pressure | Change in vital signs are monitored within 180 days after RAG-17 treatment to determine the safety and tolerability of RAG-17 on adult ALS patients. Vital sign that is measured including blood pressure in mmHg. | Within 180 days after treatment | |
| Primary | Physiological Parameter-Vital Signs: Height, Hip Circumference and Waist | Change in vital signs are monitored within 180 days after RAG-17 treatment to determine the safety and tolerability of RAG-17 on adult ALS patients. Vital signs that are measured including height, hip circumference and waist in centimeter. | Within 180 days after treatment | |
| Primary | Physiological Parameter-Vital Signs: Weight | Change in vital signs are monitored within 180 days after RAG-17 treatment to determine the safety and tolerability of RAG-17 on adult ALS patients. Vital sign that is measured including body weight in kilogram. | Within 180 days after treatment | |
| Primary | Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) | Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) is a questionnaire-based scale that is used to measure the change in functional impairment of adult ALS patients within 180 days after RAG-17 treatment. ALSFRS-R scale measures 12 aspects of physical function, and each function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. | Within 180 days after treatment | |
| Primary | Neurological examinations | Incidence rate of abnormalities in neurological examinations within 180 days after RAG-17 treatment | Within 180 days after treatment | |
| Primary | Heart circulatory system examinations | Incidence rate of abnormalities in heart circulatory system examinations within 180 days after RAG-17 treatment | Within 180 days after treatment | |
| Primary | Respiratory system examinations | Incidence rate of abnormalities in respiratory system examinations within 180 days after RAG-17 treatment | Within 180 days after treatment | |
| Primary | Abdominal examinations | Incidence rate of abnormalities in abdominal examinations within 180 days after RAG-17 treatment | Within 180 days after treatment | |
| Primary | ECG results | Incidence rate of abnormalities in ECG results within 180 days after RAG-17 treatment | Within 180 days after treatment | |
| Secondary | SOD1 protein levels | Changes of SOD1 protein levels in cerebrospinal fluid from baseline on day 1, day 15, day 29, day 60, day 120, day 180 and day 240 of adult ALS patients after RAG-17 treatment | day 1, day 15, day 29, day 60, day 120, day 180 and day 240 | |
| Secondary | Plasma neurofilament light (NFL) levels | Changes in plasma neurofilament light (NFL) levels from baseline on day 1, day 15, day 29, day 60, day 120, day 180 and day 240 in adult ALS patients after RAG-17 treatment | day 1, day 15, day 29, day 60, day 120, day 180 and day 240 | |
| Secondary | Pharmacokinetic Changes of RAG-17 | Pharmacokinetic Parameter changes of RAG-17 in Plasma: Maximum Observed Concentration (Cmax) on day1, day15, day29, day60, day120, day180 and day240 in adult ALS patients after RAG-17 treatment | day 1, day 15, day 29, day 60, day 120, day 180 and day 240 | |
| Secondary | Pharmacokinetic Changes of RAG-17 | Pharmacokinetic Parameter changes of RAG-17 in Plasma: Time to Reach Maximum Observed Concentration (Tmax) on day1, day15, day29, day60, day120, day180 and day240 in adult ALS patients after RAG-17 treatment | day 1, day 15, day 29, day 60, day 120, day 180 and day 240 | |
| Secondary | Pharmacokinetic Changes of RAG-17 | Pharmacokinetic Parameter changes of RAG-17 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) on day1, day15, day29, day60, day120, day180 and day240 in adult ALS patients after RAG-17 treatment | day 1, day 15, day 29, day 60, day 120, day 180 and day 240 | |
| Secondary | Pharmacokinetic Changes of RAG-17 | Pharmacokinetic Parameter changes of RAG-17 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast) on day1, day15, day29, day60, day120, day180 and day240 in adult ALS patients after RAG-17 treatment | day 1, day 15, day 29, day 60, day 120, day 180 and day 240 | |
| Secondary | Pharmacokinetic Changes of RAG-17 | Pharmacokinetic Parameter changes of RAG-17 in Plasma: Apparent Terminal Elimination Half-life (t1/2) on day1, day15, day29, day60, day120, day180 and day240 in adult ALS patients after RAG-17 treatment | day 1, day 15, day 29, day 60, day 120, day 180 and day 240 | |
| Secondary | Mechanical ventilation | Time to invasive mechanical ventilation in adult ALS patients treated with RAG-17 | From day1 to day240 | |
| Secondary | Death | Time of death in adult ALS patients treated with RAG-17 | From randomization date to date of death from any cause. The assessment period is up to 8 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03358459 -
Omics-based Precision Medicine of Epilepsy
|
N/A | |
| Recruiting |
NCT02000089 -
The Cancer of the Pancreas Screening-5 CAPS5)Study
|
Phase 3 | |
| Recruiting |
NCT03764371 -
Effects of Different Genetic Mutations on Prognosis in sMPLC Adenocarcinoma Patients
|